Benzinga

Benzinga

Benzinga

domingo, agosto 30

Travere Therapeutics Inc

TVTXNASDAQ
Trade with Public
Trade with Public
$65.67
-1.85-2.74%
al cierre: Aug 28, 5:00 PM EST
$65.49
-0.18-0.27%
After hour: Aug 28, 6:03 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Travere Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Travere Therapeutics (TVTX).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

13Buy
2Hold
Consensus RatingBuy# Analysts15Avg. Consensus PT$49Upside to Avg. PT-24.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 10, 2026Evercore ISI GroupLiisa BaykoPT RaiseOutperform$68→$78
Aug 6, 2026Canaccord GenuityEdward NashPT RaiseBuy$62→$70
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $68 to $78.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $61 to $75.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75

TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $60 to $75.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $85.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $60 to $68.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved